{"entity":{"id":"paper-mujumdar-ivermectin-gynaecological-cancer-2025","kind":"paper","name":"Ivermectin and gynecologic cancer: what's the data?","aka":[],"tldr":"Gynaecological oncologists reviewed the evidence for ivermectin in womb, ovarian and cervical cancers, found only cell-line data, and strongly caution against using it.","summary":"The review states that ivermectin was approved by the FDA in 1996 as an oral medicine for intestinal strongyloidiasis and onchocerciasis, that data on it as a gynaecological cancer-fighting compound are lacking, and that clinical studies of ivermectin in cancer are limited to effects observed in cell lines (Mujumdar review 2025). Its authors write that they have not assessed its safety and efficacy in gynaecological cancers and 'do not recommend and strongly caution' its use (Mujumdar review 2025).","asOf":"2026-09-24","links":[{"label":"Mujumdar review 2025","url":"https://doi.org/10.1016/j.gore.2025.101803"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/40851910/"}],"tags":[],"related":[],"cancers":["ovarian","endometrial","cervical"],"sections":[],"technologies":["fenbendazole-ivermectin-repurposing-claims"],"targets":[],"drugs":["ivermectin"],"companies":[],"institutions":[],"pathways":[],"terms":["cell-line"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo agent (Claude Fable 5.1)","editedOn":"2026-09-24","note":"Written from cached ClinicalTrials.gov v2, Europe PMC, DailyMed, Drugs@FDA and WHO eEML responses; no figure appears without its source link."},"journal":"Gynecologic Oncology Reports","year":2025,"doi":"10.1016/j.gore.2025.101803","pmid":"40851910","authors":"Mujumdar V, Huang M, Smith LC, Musa F.","paperType":"review","findings":["Clinical evidence for ivermectin in gynaecological cancers is limited to cell-line studies.","The authors strongly caution against its use for these cancers."],"whatItMeans":"For a patient with a gynaecological cancer, the specialists who would run such a trial say the evidence does not exist yet.","caveats":["Review of a field with almost no clinical data; the conclusion rests on absence of evidence rather than on trials showing harm."],"changedPractice":false},"route":"/key-papers/paper-mujumdar-ivermectin-gynaecological-cancer-2025/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"technology":[{"id":"fenbendazole-ivermectin-repurposing-claims","kind":"technology","name":"Fenbendazole, ivermectin and other internet 'repurposed cures'","route":"/technologies/fenbendazole-ivermectin-repurposing-claims/"}],"drug":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/"}],"term":[{"id":"cell-line","kind":"term","name":"Cell line","route":"/terms/cell-line/"}]}}